OOIR: Observatory of International Research

Papers

(The median citation count of Therapeutic Advances in Psychopharmacology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Prevalence and predictors of inappropriate prescribing in outpatients with severe mental illness	102
Relationship between resilience and mental health among COVID-19 bereaved people: the mediating role of dual process coping	54
History repeating: guidelines to address common problems in psychedelic science	45
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review	38
A rapid clinical response to etifoxine in treatment-resistant obsessive-compulsive disorder: a case report of a patient with comorbid bipolar disorder	26
Comment on: History repeating: guidelines to address common problems in psychedelic science	25
The missing link? Pharmacists’ perspectives on discontinuation of long-term antidepressants: a qualitative study	25
Disrupted emotion regulation and spontaneous neural activity in panic disorder: a resting-state fMRI study	24
Incidence of hyperthyroidism in patients with bipolar or schizoaffective disorder with or without lithium: 21-year follow-up from the LiSIE retrospective cohort study	23
Psychotropic medications versus non-pharmacologic approaches for managing behavioural and psychological symptoms in Australian aged care residents with dementia: general practitioners’ and physicians’	22
Adult psychiatrists’ views on clozapine prescribing for schizophrenia in Germany—an online survey	20
Sympathetic activation but not dissociation linked to ketamine’s sustained antidepressant effect	19
Corrigendum to “Managing medical and psychiatric multimorbidity in older patients”	18
Plain Language Summary of Publication: A comparison of once-monthly and once-every-2-months injectable formulations of aripiprazole in people with schizophrenia	17
Reasons for discontinuing and restarting lithium multiple times: a case-register study based on the South London and Maudsley NHS Foundation Trust Clinical Record Interactive Search system	17
Monoclonal antibody precision therapy targeting inflammation for bipolar disorder: a narrative review	17
Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychoti	14
Antipsychotics and structural brain changes: could treatment adherence explain the discrepant findings?	14
A description of antipsychotic prescribing patterns on the inpatient behavioral health setting: a multicenter cross-sectional analysis	14
Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review	13
Corrigendum to “Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis”	11
Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand	10
Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine	10
Impact of CYP1A , CYP2C19 , CYP2D6 , CYP3A4 , CYP3A5	9
Sex, drugs, and arousal—two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity	9

Corrigendum to ‘Comment on: History repeating: guidelines to address common problems in psychedelic science’	9
Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications	9
Healthcare resource savings from administering paliperidone palmitate once every 3 months instead of once every month for schizophrenia: a 12-month mirror-image analysis of real-world population-based	8
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia	8
Psychedelic therapy and postpartum depression: priorities and prospects	8
The interplay between serotonin syndrome and syndrome of inappropriate antidiuresis: a fatal case of acute hyponatremia during treatment with duloxetine, chlorphenamine, amitriptyline, and L-tryptopha	8
Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review	8
The role of empathy in antidepressant withdrawal	7
Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies	7
Anticholinergic action is rarely a good thing	7
Treating job-related stress with psychedelic group therapy: a case series on group ketamine-assisted psychotherapy for healthcare workers and first responders	6
Incorporation of a specialist mental health clinical pharmacist within a primary care network: patient referrals, prescribing decisions, and clinical outcomes	6
Decreased citalopram concentration caused by enzyme induction effect of rifampin: a case report	6
Anhedonia nonresponse to short-term ketamine administration for treatment-resistant bipolar depression	5
Corrigendum to “Psychedelic Assisted Therapy as a Complex Intervention: Implications for clinical trial design”	5
Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression	5
High-dose olanzapine in treatment-resistant schizophrenia: a systematic review	5
Preliminary data from a 4-year mirror-image and multicentre study of patients initiating paliperidone palmitate 6-monthly long-acting injectable antipsychotic: the Paliperidone 2 per Year study	4
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series	4
The role of flumazenil in generalised anxiety disorder: a pilot naturalistic open-label study with a focus on treatment resistance	4
Levels of aripiprazole in the blood with an injection of aripiprazole administered once every two months: a plain language summary of publication	3
Tardive dyskinesia: understanding current challenges in diagnosis and treatment	3
Ketamine-assisted therapy within a community of practice: a novel approach to disordered eating	3
The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics	3
Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen Area	3
Predicting rTMS treatment response in schizophrenia using interpretable machine learning: a SHAP-based analysis	3
The cardiovascular safety of tricyclic antidepressants in overdose and in clinical use	3
Risperidone ISM^®: review and update of its usefulness in all phases of schizophrenia	3
Drug safety in older patients with alcohol use disorder: a retrospective cohort study	3
Impact of treatment with long‑acting injectable antipsychotics on hospitalization and relapse rates in schizophrenia spectrum disorders: a 3‑year follow-up mirror‑image study	3
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence	2
Altered orbitofrontal and pars opercularis cortical thickness in betel quid dependence chewers	2
Clinical predictors of stimulant efficacy in adults with ADHD	2
Olanzapine for the treatment of ICU delirium: a systematic review and meta-analysis	2
Psychosocial interventions to improve adherence in depressed and anxious older adults prescribed antidepressant pharmacotherapy: a scoping review	2
The place of long-acting injectable antipsychotics in the treatment of schizophrenia	2
Managing medical and psychiatric multimorbidity in older patients	2
The acute effects of Zensera™ ( Melissa officinalis L. ) extract on mood and cognitive performance during cognitive overload: a randomised placebo-contro	1
MicroRNAs in metabolic effects with atypical antipsychotics—a scoping review	1
Drug utilization in geriatric psychiatric patients in the emergency department—a cohort study under real-world conditions	1
Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis	1
Frequency of anticholinergic drug use in patients treated with aripiprazole once-monthly: a 2-year cohort study using European healthcare databases	1
Ketamine dosing formula in treatment-resistant bipolar depression	1
The past, present and future of anticholinergic drugs	1
Sublingual asenapine for agitation in malabsorptive states: three patient cases	1
From model psychosis to rapid antidepressant: a historical and conceptual review of ketamine’s psychiatric history	1
Oral contraceptive formulation and socio-cognitive performance: a short communication	1
Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery	1
Psychotropic medications adherence status and its determinants among older adults with severe affective and psychotic disorders: a multicenter cross-sectional study	1
Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an in silico modelling study	1

Preventing and treating delirium in clinical settings for older adults	1
Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis	1